{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:17:53Z","timestamp":1787807873009,"version":"build-2784847793"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,25]],"date-time":"2027-06-25T00:00:00Z","timestamp":1813881600000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013401","name":"Ovarian Cancer Research Fund Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jconrel.2026.115120","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:33:38Z","timestamp":1781800418000},"page":"115120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration"],"prefix":"10.1016","volume":"397","author":[{"given":"Haining","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda I.","family":"Rakoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkwan","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby N.","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Catazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua C.","family":"Doloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia J.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115120_bb0005","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jconrel.2026.115120_bb0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2026.115120_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.jconrel.2026.115120_bb0020","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2026.115120_bb0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/IAE.0b013e3181669504","article-title":"Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation","volume":"28","author":"Freund","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2026.115120_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.115120_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101113","article-title":"Towards a better understanding of non-exudative choroidal and macular neovascularization","volume":"92","author":"Sacconi","year":"2023","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.115120_bb0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/IAE.0000000000003945","article-title":"From Drusen to type 3 macular neovascularization","volume":"44","author":"Bousquet","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2026.115120_bb0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/IAE.0b013e3181619c55","article-title":"Review of retinal angiomatous proliferation or type 3 neovascularization","volume":"28","author":"Yannuzzi","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2026.115120_bb0050","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/IAE.0000000000001268","article-title":"An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography","volume":"36","author":"Su","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2026.115120_bb0055","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00006982-200312000-00001","article-title":"Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis","volume":"23","author":"Gass","year":"2003","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2026.115120_bb0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115120_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40266-013-0077-9","article-title":"Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration","volume":"30","author":"Frampton","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jconrel.2026.115120_bb0070","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115120_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.115120_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115120_bb0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2026.115120_bb0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14728222.2022.2030706","article-title":"Disease progression pathways of wet AMD: opportunities for new target discovery","volume":"26","author":"Wolf","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jconrel.2026.115120_bb0095","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41433-023-02610-z","article-title":"Tyrosine kinase inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema","volume":"37","author":"Chandra","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.jconrel.2026.115120_bb0100","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.jconrel.2026.115120_bb0105","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115120_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00479","article-title":"Comparative efficacy, safety, and costs of Sorafenib vs. Sunitinib as first-line therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"9","author":"Deng","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115120_bb0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0025-6196(11)60847-1","article-title":"Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration","volume":"83","author":"Diago","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jconrel.2026.115120_bb0120","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0420.2007.01014.x","article-title":"Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib\u00ae treatment","volume":"86","author":"Kernt","year":"2008","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.115120_bb0125","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bjo.2010.182162","article-title":"Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF","volume":"94","author":"Kernt","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.115120_bb0130","author":"Ocular Therapeutix, Inc."},{"key":"10.1016\/j.jconrel.2026.115120_bb0135","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41467-020-14340-x","article-title":"Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles","volume":"11","author":"Tsujinaka","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115120_bb0140","author":"Graybug Vision"},{"key":"10.1016\/j.jconrel.2026.115120_bb0145","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1038\/s41433-023-02496-x","article-title":"Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study","volume":"37","author":"Gao","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.jconrel.2026.115120_bb0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/24741264241308496","article-title":"So many injections, so much waste: understanding the environmental impact of intravitreal injections","volume":"9","author":"Grodsky","year":"2024","journal-title":"J. Vitreoretin. Dis."},{"key":"10.1016\/j.jconrel.2026.115120_bb0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.115120_bb0160","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12195-021-00708-6","article-title":"Crystallization of the multi-receptor tyrosine kinase inhibitor sorafenib for controlled long-term drug delivery following a single injection","volume":"14","author":"Lai","year":"2021","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.jconrel.2026.115120_bb0165","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41563-019-0377-5","article-title":"Long-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulations","volume":"18","author":"Farah","year":"2019","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.115120_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122043","article-title":"The antisolvent coprecipitation method for enhanced bioavailability of poorly water-soluble drugs","volume":"626","author":"Zhang","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115120_bb0175","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/nprot.2013.135","article-title":"Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice","volume":"8","author":"Lambert","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2026.115120_bb0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1167\/iovs.07-0870","article-title":"Expression of VLDLR in the retina and evolution of subretinal neovascularization in the knockout mouse model\u2019s retinal angiomatous proliferation","volume":"49","author":"Hu","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.115120_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ces.2021.117067","article-title":"Flow-through microscopy and image analysis for crystallization processes","volume":"248","author":"Vancleef","year":"2022","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.jconrel.2026.115120_bb0190","doi-asserted-by":"crossref","first-page":"o29","DOI":"10.1107\/S0108270110047451","article-title":"Sorafenib and its tosyl\u00adate salt: a multikinase inhibitor for treating cancer","volume":"67","author":"Ravikumar","year":"2011","journal-title":"Acta Cryst. C"},{"key":"10.1016\/j.jconrel.2026.115120_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molliq.2010.11.003","article-title":"Effect of acetonitrile on the micellization and thermodynamic parameters of tetradecyltrimethylammonium bromide: conductometric and fluorimetric studies","volume":"158","author":"Kabir-ud-Din","year":"2011","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.jconrel.2026.115120_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132643","article-title":"Optimization of an image-guided laser-induced choroidal neovascularization model in mice","volume":"10","author":"Gong","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jconrel.2026.115120_bb0205","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12974-024-03190-9","article-title":"Suppression of inner blood-retinal barrier breakdown and pathogenic M\u00fcller glia activation in ischemia retinopathy by myeloid cell depletion","volume":"21","author":"Zhou","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jconrel.2026.115120_bb0210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12974-024-03329-8","article-title":"Ibuprofen reduces inflammation, necroptosis and protects photoreceptors from light-induced retinal degeneration","volume":"22","author":"Zhang","year":"2025","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jconrel.2026.115120_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140451","article-title":"Study on several novel crystalline complexes of sorafenib with dicarboxylic acid: nature identification and solubilization mechanism","volume":"1323","author":"Wang","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.jconrel.2026.115120_bb0220","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1007\/s11164-022-04777-8","article-title":"Formulation and therapeutic efficacy of PEG-liposomes of sorafenib for the production of NL-PEG-SOR FUM and NL-PEG-SOR TOS","volume":"48","author":"Mahmoodi","year":"2022","journal-title":"Res. Chem. Intermed."},{"key":"10.1016\/j.jconrel.2026.115120_bb0225","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s12257-019-0512-9","article-title":"Albumin: an emerging opportunity in drug delivery","volume":"25","author":"Rahimizadeh","year":"2020","journal-title":"Biotechnol. Bioprocess. E"},{"key":"10.1016\/j.jconrel.2026.115120_bb0230","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115120_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11092445","article-title":"Neovascular progression and retinal dysfunction in the laser-induced choroidal neovascularization mouse model","volume":"11","author":"Salas","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.115120_bb0240","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1167\/iovs.10-6266","article-title":"In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography","volume":"52","author":"Giani","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.115120_bb0245","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1006\/exer.2000.0907","article-title":"Quantitative image analysis of laser-induced choroidal neovascularization in rat","volume":"71","author":"Edelman","year":"2000","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2026.115120_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.734860","article-title":"Clinical pathological features and current animal models of Type 3 macular neovascularization","volume":"15","author":"Qiang","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jconrel.2026.115120_bb0255","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0002-9440(10)65753-7","article-title":"Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model","volume":"153","author":"Tobe","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115120_bb0260","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/11206721241275206","article-title":"Non-exudative choroidal and macular neovascularizations: an overview","volume":"35","author":"Berni","year":"2025","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.115120_bb0265","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1167\/iovs.10-6496","article-title":"Resveratrol inhibits pathologic retinal neovascularization in Vldlr\u2212\/\u2212 mice","volume":"52","author":"Hua","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.115120_bb0270","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.preteyeres.2005.01.004","article-title":"Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases","volume":"24","author":"Jonas","year":"2005","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.115120_bb0275","unstructured":"Foscarnet Calcium Microcrystals as the Intravitreal Drug Depot - Chemical Communications (RSC Publishing), (n.d.). https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2017\/cc\/c7cc02399e (accessed May 26, 2026)."},{"key":"10.1016\/j.jconrel.2026.115120_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10523","article-title":"Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration","volume":"8","author":"Zhu","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115120_bb0285","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jconrel.2022.03.012","article-title":"Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes","volume":"345","author":"McGuckin","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115120_bb0290","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jconrel.2023.09.021","article-title":"Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration","volume":"363","author":"Chacin Ruiz","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115120_bb0295","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s12272-024-01503-3","article-title":"The challenges and opportunities of developing small-molecule therapies for age-related macular degeneration","volume":"47","author":"Fei","year":"2024","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115120_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102322","article-title":"Treatment avenues for age-related macular degeneration: breakthroughs and bottlenecks","volume":"98","author":"Kumbhar","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.jconrel.2026.115120_bb0305","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2026.115120_bb0310","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115120_bb0315","doi-asserted-by":"crossref","first-page":"6","DOI":"10.14227\/DT080301P6","article-title":"Dissolution method development for poorly soluble compounds","volume":"8","author":"Rohrs","year":"2001","journal-title":"Dissol. Technol."},{"key":"10.1016\/j.jconrel.2026.115120_bb0320","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/acs.cgd.2c01323","article-title":"Batch crystallization of xylitol by cooling, evaporative, and antisolvent crystallization","volume":"23","author":"Zaykovskaya","year":"2023","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.jconrel.2026.115120_bb0325","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1021\/acs.cgd.2c00014","article-title":"Three-step mechanism of antisolvent crystallization","volume":"22","author":"Dighe","year":"2022","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.jconrel.2026.115120_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103884","article-title":"Untangling \u201cdissolved\u201d drug species from various formulations of a poorly soluble drug: sampling methods, mechanistic insights, and IVIVC","volume":"114","author":"Lynnerup","year":"2025","journal-title":"J. Pharm. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:25:52Z","timestamp":1787804752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":66,"alternative-id":["S0168365926005237"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115120","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115120"}}